Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $67 to $23.
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $67 to $23.